The Motley Fool··Prosper Junior BakinyVertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams
Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.
VRTXCRSPclinical trialspipeline candidates